BofA Securities upgraded Alcon from Neutral to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2026 | $97.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2026 | Mkt Perform | William Blair | |
| 1/20/2026 | Hold → Buy | Deutsche Bank | |
| 1/9/2026 | Buy → Hold | Stifel | |
| 12/11/2025 | $75.00 | Buy → Underperform | BofA Securities |
| 8/21/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Hold | Deutsche Bank | |
| 5/14/2025 | $102.00 → $99.00 | Buy | BTIG Research |
Wells Fargo upgraded Alcon from Equal Weight to Overweight and set a new price target of $97.00
William Blair initiated coverage of Alcon with a rating of Mkt Perform
Deutsche Bank upgraded Alcon from Hold to Buy
New partnership raises awareness of dry eye, a condition affecting an estimated 8.5 million Canadians1, helping fans stay comfortable throughout the game. This season, Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that Systane® has partnered with the Toronto Blue Jays as the official eye drop of the team. The partnership aims to help Canadians recognize the signs of dry eye and stay comfortable throughout the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407095429/en/Systane Steps Up to the Plate as the Official Eye Drop of the Toronto Blue Jays, Raising Awareness of Dr
TruPlus is designed to increase depth of focus while maintaining the high-quality distance vision surgeons expect from a monofocal IOL1,2 TruPlus demonstrates higher distance image quality across pupil sizes and lighting conditions than TECNIS Eyhance3,* At ASCRS, Alcon will also feature more than 60 scientific presentations and peer-to-peer educational symposia Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of Clareon® TruPlus, its new enhanced design monofocal and toric intraocular lens (IOL), at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. TruP
Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
Alcon welcomes its shareholders to its fourth in-person AGM Alcon Board of Directors proposes to elect R. Scott Herren as a new independent Board member Proposed dividend of CHF 0.28 cash per share Alcon (SIX/NYSE:ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on April 30, 2026. Alcon is pleased to welcome shareholders to its fourth in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. Alcon's Board of Directors proposes to the AGM to elect R. Scott Herren as a new independent Board member. An accomplished financial executive with thirty-
Fourth-quarter 2025 sales of $2.7 billion, up 9% on a reported basis, or up 7% constant currency1 (cc), versus fourth-quarter 2024 Fourth-quarter 2025 diluted EPS of $0.44; core diluted EPS2 of $0.78 Generated $2.3 billion of cash from operations and $1.7 billion of free cash flow3 in full-year 2025 Returned $848 million to shareholders through share repurchases and dividends Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and twelve month periods ending December 31, 2025. For the fourth quarter of 2025, sales were $2.7 billion, up 9% on a reported basis and up 7% on a constant curren
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine month periods ending September 30, 2025. For the third quarter of 2025, sales were $2.6 billion, up 6% on a reported basis and up 5% on a constant c